GraniteShares Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
GraniteShares Advisors's VRTX Position: Q2 2026 in Review
GraniteShares Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, selling an estimated $105K and leaving 1,820 shares worth $904K. The position accounts for 0.58% of the portfolio, ranked #54.
GraniteShares Advisors first reported a position in VRTX in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.32M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- GraniteShares Advisors held 1,820 shares of Vertex Pharmaceuticals worth $904K as of Q2 2026.
- GraniteShares Advisors sold 238 Vertex Pharmaceuticals shares in Q2 2026, an estimated $105K.
- Vertex Pharmaceuticals made up 0.58% of GraniteShares Advisors's portfolio in Q2 2026, its #54 holding.
- GraniteShares Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
- GraniteShares Advisors's Vertex Pharmaceuticals position peaked at $1.32M in Q2 2024.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on GraniteShares Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.